ORPRO THERAPEUTICS INC
Theradux, a non-systemic biologic drug platform for lung and epithelial surface diseases
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Latest Form D
- $1.3M, Dec 2013
- Total capital
- $4M
- Federal grants
- $2.7M
- 5 awards · 2018–2025
- Rank in peer group#245 of 392
- Private capital raised
- $1.3M
- 1 Form D · last Dec 2013
- 154 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 8 pending · first 2015
- Rank in peer group#53 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Engineered Monothiol Thioredoxin for Treatment of Radiation Induced Lung Injury$509K
- Federal grantHealth and Human S · Phase II · Development of modified human thioredoxin as an inhaled biologic therapeutic for cystic fibrosis$1.5M
- Federal grantHealth and Human S · Phase I · Mucoadhesive drug conjugates for controlled-release inhalation delivery$228K
- Federal grantHealth and Human S · Phase I · Mucoadhesive drug conjugates for controlled-release inhalation delivery$228K
- Federal grantHealth and Human S · Phase II · Development of modified human thioredoxin as an inhaled biologic therapeutic for cystic fibrosis$224K
- Private capital raisedForm D · SEC · 1st filing$1.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#53 · top 14%
- Linked publications#18 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Cam L. GarnerExecutive Officer, DirectorNamed in SEC Form D filings
- James W. WeilDirectorNamed in SEC Form D filings
- Jeffrey W. RaserDirectorNamed in SEC Form D filings
- Mary Jacqueline JohnsonDirectorNamed in SEC Form D filings
- Peter B. Heifetz, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 10- PendingProduct And Process For Mucus Viscosity NormalizationUSPTOApplication 19292329
- GrantedProduct and Process for Mucus Viscosity NormalizationUSPTOUS 12,390,511
- PendingThiol-based Multivalent Drug Delivery CompositionsUSPTOApplication 18733200
Show all 10 patent records
- Product And Process For Mucus Viscosity NormalizationJan 29, 2026 · Application 19292329Pending
- Product and Process for Mucus Viscosity NormalizationAug 19, 2025 · US 12,390,511Granted
- Thiol-based Multivalent Drug Delivery CompositionsOct 31, 2024 · Application 18733200Pending
- Compositions Having Thioredoxin Activity And Related MethodsMar 9, 2023 · Application 17758352Pending
- Thiol-based Multivalent Drug Delivery CompositionsJul 15, 2021 · Application 17056151Pending
- Product And Process For Mucus Viscosity NormalizationAug 11, 2016 · Application 14852113Pending
- Product And Process For Mucus Viscosity NormalizationOct 27, 2015 · US 9,168,290Granted
- Compositions Having Thioredoxin Activity And Related MethodsApplication PCTUS2021012109Pending
- Thiol-based Multivalent Drug Delivery CompositionsApplication PCTUS2019032932Pending
- Product And Process For Mucus Viscosity NormalizationApplication PCTUS2014030545Pending
Recent research by its founders
- Optimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation20250 cites
- Development of Thioredoxin Monothiol Derivatives for Mitigating Radiation Induced Hematopoietic Injury20230 cites
- Supporting US public health experts20200 cites
Related companies, and why
- Entos Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- Onramp BioInformatics, Inc.Similar federal contract value in Biotech · null in contracts
- 4E THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Pierogi Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
- Atrin PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- BrainTrust BIO Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .